2022 年実績
論文（英文）
1. Suga D, Mizutani H, Fukui S, Kobayashi M, Shimada Y, Nakazawa Y, Nishiura Y,Kawasaki Y, Moritani I, Yamanaka Y, Inoue H, Ojima E, Mohri Y, Nakagawa H, Dohi K,Takaba K, Wada H, Shiraki K. The gut microbiota composition in patients with rightand left-sided colorectal cancer and after curative colectomy, as analyzed by 16S rRNA
gene amplicon sequencing. BMC Gastroenterol. 2022 Jun 25;22(1):313.
2. Fukui S, Ito H, Moritani I, Shiraki K. Massive hepatic portal venous gas caused bygastric emphysema. BMJ Case Rep. 2022 Jul 11;15(7):3. Kinoshita T, Shinoda M, Nishizaki Y, Shiraki K, Hirai Y, Kichikawa Y, Tsushima K,Shinkai M, Komura N, Yoshida K, Kido Y, Kakeya H, Uemura N, Kadota J. A
multicenter, double-blind, randomized, parallel-group, placebo-controlled study toevaluate the efficacy and safety of camostat mesilate in patients with COVID-19(CANDLE study). BMC Med. 2022 Sep 27;20(1):342.
4. Platelet Activation and Thrombosis in COVID-19.
Iba T, Wada H, Levy JH.Semin Thromb Hemost. 2023 Feb; 49(1): 55-61.
5. Predictive prognostic biomarkers in patients with COVID-19 infection.
6. Fukui S, Ikeda K, Kobayashi M, Nishida K, Yamada K, Horie S, Shimada Y, Miki H,Goto H, Hayashi K, Nakazawa Y, Mizutani H, Kamon T, Tanigaito Y, Kodama S, KatoT, Nishiura Y, Suga D, Terashima T, Ichikawa Y, Moritani I, Yamamoto A, Takaba K,Yasumoto K, Wada H, Shiraki K.Mol Med Rep. 2023 Jan; 27(1): 15.
7.

"Unconventional CD147-dependent platelet activation elicited by SARS-CoV-2 in
COVID-19": Comment from Wada et al.
Wada H, Shiraki K, Suzuki-Inoue K.J Thromb Haemost. 2022 Sep; 20(9): 2159-2160.

8. Proposal of Quick Diagnostic Criteria for Disseminated Intravascular Coagulation.
Wada H, Yamamoto A, Tomida M, Ichikawa Y, Ezaki M, Masuda J, Yoshida M, Fukui S,Moritani I, Inoue H, Shiraki K, Suzuki K, Imai H, Shimaoka M, Shimpo H.J Clin Med.
2022 Feb 16; 11(4): 1028.
9. D-dimer kit with a High FDP/D-Dimer Ratio is Useful for Diagnosing ThromboticDiseases.
Ikeda N, Wada H, Ichikawa Y, Ezaki M, Tanaka M, Hiromori S, Shiraki K, Moritani I,Yamamoto A, Shimpo H, Shimaoka M. Clin Appl Thromb Hemost. 2022 Jan-Dec; 28:10760296211070584
10. Elevated Plasma Soluble C-Type Lectin-like Receptor 2 Is Associated with theWorsening of Coronavirus Disease 2019.
11. Wada H, Ichikawa Y, Ezaki M, Yamamoto A, Tomida M, Yoshida M, Fukui S, MoritaniI,Shiraki K, Shimaoka M, Iba T, Suzuki-Inoue K, Shimpo H.

12. A Clot Waveform Analysis of Thrombin Time Using a Small Amount of Thrombin Is
Useful for Evaluating the Clotting Activity of Plasma Independent of the Presence ofEmicizumab.
Wada H, Shiraki K, Matsumoto T, Suzuki K, Yamashita Y, Tawara I, Shimpo H,Shimaoka M.J Clin Med. 2022 Oct 18; 11(20): 6142.
13. The gut microbiota composition in patients with right- and left-sided colorectal cancer
and after curative colectomy, as analyzed by 16S rRNA gene amplicon sequencing.
Suga D, Mizutani H, Fukui S, Kobayashi M, Shimada Y, Nakazawa Y, Nishiura Y,Kawasaki Y, Moritani I, Yamanaka Y, Inoue H, Ojima E, Mohri Y, Nakagawa H, Dohi K,Takaba K, Wada H, Shiraki K.BMC Gastroenterol. 2022 Jun 25; 22(1): 313. Cite
14. Endovascular Treatment for Lower-extremity Arterial Thrombosis in a Patient with
Congenital Afibrinogenemia and a History of Bleeding Complications.
Hiramatsu D, Ogihara Y, Matsumoto T, Sato K, Takasaki A, Kurita T, OkamotoR, Wada H, Dohi K. Intern Med. 2022 Feb 1; 61(3): 361-364.
和文
1. 和田英夫：血小板活性化マーカーとしての soluble CLEC-2（sCLEC-2）の測定意義、日本臨床化学会会誌『臨床化学』2022：51（3）、252

2. 和田英夫、市川由布子：ISTHDIC 診断基準、徹底ガイド-DIC のすべて-2022-23、救急集中治療、vol 34、臨時増刊号 2022、総合医学社、特集編集 丸藤 哲、pp664668、2022

3. 和田英夫、江崎実：わが国のエキスパートコンセンサス、徹底ガイド-DIC のすべて2022-23、救急集中治療、vol 34、臨時増刊号 2022、総合医学社、特集編集 丸藤哲、pp698-703、2022

4. 和田英夫、池田望：ISTH DIC 診療ガイダンス、徹底ガイド-DIC のすべて-2022-23、救急集中治療、vol 34、臨時増刊号 2022、総合医学社、特集編集 丸藤 哲、pp710714、2022

学会発表
国際学会
1. Wada H: A clot waveform analysis showing a hypercoagulable state in patients withmalignant neoplasms. Symposium of World Cancer Research (SWCR) 2022, May6-8,2022 in Singapore, Web meeting
2. Wada H, Maruyama S, Kato N, Teranishi H, Matsumoto M: Classification of Japanesepatients with aHUS treated with eculizumab by a diagnostic scoring system. ISTH 2022
Congress (London July 9-13)

3. Wada H, Shiraki K, Shimaoka M, Shimpo H: Evaluation of thrombin burst using
thrombin time of clot waveform analysis. ISTH 2022 Congress (London July 9-13)
4. Wada H: Proposal of quick diagnostic criteria for disseminated intravascular
coagulation. 12th Edition of Virtual Conference on NURSING EDUCATION &PRACTICE (December 12, 2022) Web Conference
国内学会
1. 和田英夫： CWA 解析の UPDATE、第 16 回日本血栓止血学会 SSC シンポジウム、2022、2 月 19 日（東京）2. 和田英夫： 血小板活性化に伴う COVID-19 感染症の止血異常、日本血栓止血学会・日本救急医学会ジィントシンポジウム、第 44 回日本血栓止血学会学術集会,2022 年 6月 23-25
3. 和田英夫: 急性期脳梗塞などの診断において、血小板活性化マーカである血漿 sCLEC2 測定の意義、日本検査血液学会/日本血栓止血学会ジョイントシンポジウム「知る人ぞ知る血栓止血関連マーカー、第 23 回日本検査血液学会学術集会（東大本郷キヤンパス） 2022 年 7 月 30-31 日